A new promising treatment in systemic sclerosis: 5-fluorouracil

Casas, Jorge; Subauste, Carlos P.; Alarcón, Graciela S.

dc.contributor.author	Casas, Jorge
dc.contributor.author	Subauste, Carlos P.
dc.contributor.author	Alarcón, Graciela S.
dc.date.accessioned	2022-10-25T19:54:09Z
dc.date.available	2022-10-25T19:54:09Z
dc.date.issued	1987
dc.identifier.uri	https://hdl.handle.net/20.500.12866/12445
dc.description.abstract	Twelve patients with systemic sclerosis according to American Rheumatism Association criteria were treated with intravenous 5-fluorouracil. Significant subjective and objective improvement occurred initially in the skin and subsequently in the involved viscera and vasculature. These preliminary results suggest that 5-fluorouracil may be an effective treatment for systemic sclerosis.	en_US
dc.language.iso	eng
dc.publisher	BMJ Publishing Group
dc.relation.ispartofseries	Annals of the Rheumatic Diseases
dc.rights	info:eu-repo/semantics/restrictedAccess
dc.subject	systemic sclerosis	en_US
dc.subject	5-fluorouracil	en_US
dc.title	A new promising treatment in systemic sclerosis: 5-fluorouracil	en_US
dc.type	info:eu-repo/semantics/article
dc.identifier.doi	https://doi.org/10.1136/ard.46.10.763
dc.subject.ocde	https://purl.org/pe-repo/ocde/ford#3.02.17
dc.subject.ocde	https://purl.org/pe-repo/ocde/ford#3.01.03
dc.relation.issn	1468-2060